Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

35.00
-2.6800-7.11%
Post-market: 35.000.00000.00%16:10 EST
Volume:505.29K
Turnover:17.76M
Market Cap:1.57B
PE:-14.63
High:39.21
Open:38.18
Low:34.06
Close:37.68
52wk High:44.89
52wk Low:4.81
Shares:44.90M
Float Shares:25.72M
Volume Ratio:1.10
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3917
EPS(LYR):-5.8181
ROE:-24.43%
ROA:-16.64%
PB:4.06
PE(LYR):-6.02

Loading ...

MBX Biosciences Executives to Present at Major Healthcare Investor Conferences

Reuters
·
Yesterday

MBX Biosciences Raises $87 Million in ATM Offering

TIPRANKS
·
Feb 06

Microbix to Release Q1 2026 Results and Host Investor Webinar on February 12

TIPRANKS
·
Feb 05

MBX Biosciences Initiated at Overweight by Barclays

Dow Jones
·
Jan 28

MBX Biosciences initiated with an Overweight at Barclays

TIPRANKS
·
Jan 28

MBX Biosciences Appoints Laurie Stelzer as Board Director and Audit Committee Chair

Reuters
·
Jan 22

Is MBX Biosciences’ (MBX) Once‑Monthly Obesity Strategy Quietly Redefining Its Competitive Moat?

Simply Wall St.
·
Jan 19

MBX Biosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 16

Nasdaq Net Change Percentage Gainers & Losers

Dow Jones
·
Jan 16

MBX Biosciences Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy

Reuters
·
Jan 14

MBX Biosciences, Inc. (MBX) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
Jan 13

MBX Biosciences provides update on clinical programs

TIPRANKS
·
Jan 12

BRIEF-Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026

Reuters
·
Jan 12

MBX Biosciences Projects Cash Reserves Will Fund Operations Into 2029

Reuters
·
Jan 12

Mbx Biosciences Inc - Phase 3 Trial of Canvuparatide to Start in Q3 2026

THOMSON REUTERS
·
Jan 12

Mbx Biosciences to Provide 2026 Outlook and Business Update at 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 12

Mbx Biosciences Inc - Two New Obesity Candidates to Be Nominated in 2026

THOMSON REUTERS
·
Jan 12

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 12

Is UBS’s Canvuparatide Focus Altering The Investment Case For MBX Biosciences (MBX)?

Simply Wall St.
·
Jan 10

Microbix Tightens EBITDA Disclosure After OSC Review

TIPRANKS
·
Jan 09